The Claim
In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide and dulaglutide exhibit comparable rates of severe hypoglycemia (0.7%) and pancreatitis (0.6%), indicating no difference in the risk of these serious adverse events between the two drugs.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and heart disease, the rates of severe low blood sugar and pancreatitis are about the same for tirzepatide and dulaglutide, meaning neither drug appears to cause more of these serious side effects than the other.
See the scientific wording
Tirzepatide and dulaglutide have similar rates of severe hypoglycemia (0.7% each) and pancreatitis (0.6% each) in adults with type 2 diabetes and atherosclerotic cardiovascular disease, indicating no increased risk of these serious adverse events with tirzepatide.
Both drugs work by mimicking natural signals that help the body control blood sugar and reduce appetite. They both make the pancreas release insulin only when blood sugar is high, which lowers the chance of blood sugar dropping too low. They also don’t strongly trigger inflammation in the pancreas, so neither causes more pancreatitis than the other.
What the research says
1 studyStudy: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
This study compared two diabetes drugs, tirzepatide and dulaglutide, in people with heart disease and found that both had similar rates of serious side effects like low blood sugar and pancreatitis. So, tirzepatide doesn’t seem riskier than dulaglutide for these problems.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.